TFF Pharmaceuticals Announces Completion of Dosing of Phase 1b Study for Voriconazole Inhalation Powder in Mild to Moderate Asthma Patients

NEXT STORY
Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 10 Million Shares of its Common Stock
PREV STORY
Global Clinical Trial Supplies Market (2021 to 2026) – Industry Trends, Share, Size, Growth, Opportunity and Forecasts
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Checkpoint Therapeutics Appoints Christian Béchon to its Board of Directors

NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), ...

author_avatar
NASDAQ Market News

JDRF and Sun Life Financial team up to raise funds for diabetes research

TORONTO, ON--(Marketwired - September 18, 2017) - The JDRF Revolution Ride to Defeat Diabetes, ...

author_avatar
NASDAQ Market News

EyePoint Pharmaceuticals Presents Positive YUTIQ™ 24-month Follow-up Data at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting

WATERTOWN, Mass., Oct. 29, 2018 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharmaceutical ...

author_avatar
NASDAQ Market News